

Please type a plus sign (+) inside this box → []

Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 a collection of information unless it displays a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
 Assistant Commissioner for Patents
 Box RCE
 Washington, D.C. 20231

Application Number	09/467,333
Filing Date	December 20, 1999
First Named Inventor	Douglas J. Dobrozsi
Group Art Unit	1617
Examiner Name	H. Nguyen
Attorney Docket Number	7804
Confirmation Number	2248

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.
 NOTE: Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

1. Submission required under 37 C.F.R. § 1.114

- a. ☐ Previously submitted
 i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
 (Any unentered amendment(s) referred to above will be entered).
 ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 iii. ☐ Other _____
 b. Enclosed
 i. ☒ Amendment/Reply
 ii. ☐ Affidavit(s)/Declaration(s)
 iii. ☐ Information Disclosure Statement (IDS)
 iv. ☐ Other _____

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
 b. ☐ Other _____

3. Fees

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 16-2480.
 i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)
 ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
 iii. ☐ Suspension of action fee under 37 C.F.R. 1.17(i)
 iv. ☐ Other _____

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

11/01/2002 HPEOPLES 00000001 162480

01 FC:180

NAME (Print/Type)	Joan B. Cunningham	Reg. No. (Attorney/Agent)	43,982
SIGNATURE	<i>Joan B. Cunningham</i>	DATE	October 22, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being sent via facsimile to the Assistant Commissioner for Patents, Washington, DC 20231 on the date shown below:

NAME (Print/Type)	Joan B. Cunningham
SIGNATURE	<i>Joan B. Cunningham</i>
DATE	October 22, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send Fees and Completed forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, D.C. 20231.
 (Revised for P&G use 4/22/02)

Case 7804

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :
Douglas J. Dobrozsi et al. :
Request for Continuation Examination Application :
Serial No.: 09/467,333 :
Confirmation No.: 2248 : Group Art Unit: 1617
Filed: December 20, 1999 : Examiner: H. Nguyen
Title: Compositions Having Improved Stability :

AMENDMENT UNDER 37 CFR 1.114

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please amend the above-identified continuation examination application as follows and consider the accompanying remarks.

IN THE SPECIFICATION:

At page 6, please delete the paragraph at lines 1-10 and insert therefor

DI
--The actives that comprise compositions of the present invention include actives that fall into at least one of the following pharmacological classifications: antitussives; antihistamines; non-sedating antihistamines; decongestants; expectorants; mucolytics; analgesics; antipyretics; anti-inflammatory agents; local anesthetics; and mixtures thereof. References that describe the use of such actives include J. G. Hardman, The Pharmacologic Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York, 1995. Among the actives that fall in these pharmacological classifications are those that are suited for absorption through mucosal tissues. These actives can be used alone or in combination with other actives not necessarily absorbed in this manner and may be formulated within existing formulation techniques.--